会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明专利
    • Methods and compositions relating to alzheimer's disease
    • 关于阿尔茨海默病的方法和组合
    • JP2012082218A
    • 2012-04-26
    • JP2011285674
    • 2011-12-27
    • Proteome Sciences Plcプロティオーム・サイエンシィズ・ピーエルシー
    • WARD MALCOLMPATEL VAKSHAMCGREGOR EMMALEEDS NICOLABYERS HELENCAMPBELL JAMESLEUNG KIT-YIWESTBROOK JULES
    • C07K14/47A61K45/00A61P25/28C12Q1/40C12Q1/48C12Q1/533G01N27/62G01N27/64G01N33/15G01N33/68
    • G01N33/6896G01N2500/00G01N2800/2821
    • PROBLEM TO BE SOLVED: To solve problems that four drugs alone (known as cholinesterase inhibitors) out of numerous drugs used in treating the symptoms (aggressiveness, paranoia, or depression) appearing in the behaviors relating to Alzheimer's disease, namely Cognex (tacrine), Aricept (donepezil), Excelon (rivastigmine) and Reminyl (galantamine) which can be used in helping improving cognitive functions of a patient diagnosed to be suffering from AD, are only useful in a symptomatic treatment and are not found capable of altering the course of the disease.SOLUTION: There are provided methods and compositions relating to Alzheimer's disease, including proteins that are differentially expressed in Alzheimer's disease as compared to the normal state. There are further provided methods, particularly experimental paradigms, for the identification of differentially expressed proteins that are potential molecular targets for compounds for treating or preventing Alzheimer's disease. There are also provided methods for the identification and therapeutic use of compounds for preventing and treating Alzheimer's disease.
    • 要解决的问题:为了解决出现在与阿尔茨海默病相关的行为(即康耐视(Cognex))中出现的症状(侵略性,偏执狂或抑郁症)中使用的众多药物中单独使用四种药物(称为胆碱酯酶抑制剂)的问题 他克林),Aricept(多奈哌齐),Excelon(利伐斯的明)和Reminyl(加兰他敏)可用于帮助改善诊断为患有AD的患者的认知功能,仅用于对症治疗,无法改变 疾病的过程。 解决方案:提供与阿尔茨海默病有关的方法和组合物,包括与正常状态相比在阿尔茨海默氏病中差异表达的蛋白质。 还提供了用于鉴定作为治疗或预防阿尔茨海默病的化合物的潜在分子靶标的差异表达蛋白质的方法,特别是实验范例。 还提供了用于鉴定和治疗用于预防和治疗阿尔茨海默病的化合物的方法。 版权所有(C)2012,JPO&INPIT